R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics
7.6.2022 10:00:00 CEST | news aktuell GmbH | Pressemelding
Darmstadt, June 7, 2022 – R-Biopharm AG, a leading German biotechnology company operating on a global scale, announced the acquisition of AusDiagnostics. R-Biopharm is expanding its product portfolio with the addition of the Australian specialist and manufacturer of molecular biology multiplex diagnostics, extraction reagents, and laboratory automation equipment. The company is thereby unlocking new market segments in clinical diagnostics and continuing on its path of steady internationalization. “The existing and future molecular biology multiplex analysis platforms for syndrome testing from system supplier AusDiagnostics broadens our molecular biology expertise and perfectly complements our present clinical diagnostics portfolio,” states Christian Dreher, CEO of R-Biopharm. “The acquisition strengthens our position as a reliable partner for system solutions and offers our customers additional options for diagnostics.”
Upon its establishment in 2006, the Australian company introduced its patented Multiplex Tandem PCR (MT-PCR) on the market. The current technology allows the simultaneous detection of up to 24 pathogens or resistance genes from a single sample, thus shortening the lengthy test procedure in human and animal diagnostics as well as environmental, agricultural, and food analysis. The analysis platform is used in laboratories and hospitals throughout the world for detecting a broad range of diseases.
AusDiagnostics CEO Scott Gilroy said that the transaction marked an exciting new chapter for the company: “Both AusDiagnostics and R-Biopharm AG share the same commitment to innovation in the biotechnology space. This acquisition strengthens AusDiagnostics and will accelerate our global presence. We’ve experienced tremendous, industry-leading growth over the past two years, which has been underpinned by our broad suite of innovative products, talented team, and incredible, loyal customers. Joining the R-Biopharm group will allow us to further build on this and continue to deliver exceptional products and service for our Australian and international customers.”
AusDiagnostics currently has 92 employees with offices in New Zealand, the USA, and Great Britain. Its production facilities in Australia and Great Britain supply a steadily growing network of more than 25 distributors and partners around the world – from which R-Biopharm expects further synergy effects for production as well as international service and support in its clinical diagnostics line.
About R-Biopharm
R-Biopharm AG, located in Darmstadt, is one of Germany’s leading biotechnology companies. It considers itself as a pioneer for health and quality of life. The company´s aspiration is to provide the highest possible precision, safety, clarity and certainty with excellent products and solutions – in prevention, therapy and healing. Research and development at R-Biopharm has developed agile processes in order to take on new challenges to accompany a steadily growing world population into a new health era with sustainable solutions.
As an internationally recognized leader, R-Biopharm stands for the development of excellent technologies, products and solutions in the fields of Clinical Diagnostics, Nutrition Care and Food and Feed Analytics. R-Biopharm is the global market leader for test systems in the field of allergen analysis. The biotechnology company is known for its products that are of high importance for human health. To this end, it unites development, production and sales under one roof and is successfully represented in more than 120 countries worldwide – through 28 subsidiaries and 120 distributors. Founded in 1988, the family-run company employs a total of around 1,300 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the “Sustainability Award” for sustainable and profitable growth. R-Biopharm is cultivating a value-oriented corporate culture and management and is family-run in the second generation. The Chairman of the Board of Directors is Christian Dreher.
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/
https://r-biopharm.com/news-press/download-gallery/
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: +49 61 51 - 81 02-538
Mobile: +49 160 - 55 273 60
Fax: +49 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
Bilder
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
The strength of direct sales and a global community / Vorwerk increases 2025 revenue to a record EUR 3.6 billion21.5.2026 13:50:20 CEST | Press release
The Vorwerk Group closed the 2025 financial year with a new record revenue of EUR 3.6 billion despite a challenging market environment. Compared to the previous year, this corresponds to growth of 14.1 percent. The operating result also developed positively at EUR 278 million and was significantly above the previous year’s level (+28.2 percent). At the same time, the financial year marked the first year of implementation of Strategy 2030. The 2025 financial year marked the first year of implementation of Strategy 2030. The success confirms the strategic direction of the Vorwerk Group and once again underlines the strength of the Vorwerk direct sales model and the global Vorwerk community. The akf Bank, the Group’s third-largest business unit with revenue of EUR 673 million, will become even more visible as part of the Group going forward, with a new brand identity and a clear affiliation with Vorwerk.
Clean Energy Meets Wild Nature: PLAN-B NET ZERO Becomes Official Rewilding Partner of Planet Wild21.5.2026 08:48:54 CEST | Press release
(Berlin, Germany) – PLAN-B NET ZERO, the Swiss GreenTech scale-up and pioneer of the Neo Energy category, is entering a strategic partnership with Planet Wild – the Berlin-based rewilding organisation that has been redefining the global restoration movement since its founding in 2022. As the first official B2B Rewilding Partner, PLAN-B NET ZERO will support ongoing and upcoming missions to restore natural ecosystems around the world. Intact ecosystems are the foundation of a stable climate, functioning biodiversity, and liveable habitats for the long term. Yet natural habitats are under pressure worldwide: forests are disappearing, species are being lost, and entire ecosystems are falling out of balance. Rewilding addresses this directly – with the goal of restoring natural processes and giving nature the space to regenerate itself. The partnership brings together two approaches that fall short on their own: clean energy and intact nature. Because a stable climate needs both: a decarbo
European digital sovereignty: Infomaniak's founder transfers control of his company to a foundation20.5.2026 09:55:59 CEST | Press release
Geneva, 20 May 2026 — On May 13th, 2026, Boris Siegenthaler, Infomaniak's founder, transferred the majority of Infomaniak's voting rights to a new Swiss public-interest foundation. An irrevocable move, rare in Europe, that places one of the pioneers of the European Web beyond the reach of any takeover.
World’s first clearing bank for the AI era: Augustus receives conditional full service bank charter from the OCC12.5.2026 10:00:00 CEST | Press release
New York - Augustus, formerly known as Ivy, has received conditional approval from the Office of the Comptroller of the Currency (OCC), the US federal banking regulator, to establish Augustus Bank, N.A. as a full service US national bank. Augustus Bank N.A. will be the world’s first clearing bank for the AI era, built on a stablecoin and AI-native core – a bank that’s always open, made for machines, at the speed of compute.
Innomotics accelerates LNG electrification with major eLNG drive orders worldwide11.5.2026 13:37:15 CEST | Press release
Innomotics wins several orders to provide motor and drive technology for eLNG projects, totaling a volume in the higher double-digit million EUR range Innomotics advances electrification of LNG production with eLNG solutions based on electric drive systems Significant operational, environmental, and financial benefits compared to conventional turbine-based LNG plants Enables decarbonization and supports global transition to sustainable energy systems
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom